Idioma:

Long-Term Failure Patterns and Survival in a Randomized Dose-Escalation Trial for Prostate Cancer. Who Dies of Disease?

Kuban, Deborah A., M.D ; Levy, Lawrence B ; Cheung, M. Rex, M.D. Ph.D ; Lee, Andrew K., M.D., M.P.H ; Choi, Seungtaek, M.D ; Frank, Steven, M.D ; Pollack, Alan, M.D., Ph.D

International journal of radiation oncology, biology, physics, 2011-04, Vol.79 (5), p.1310-1317 [Periódico revisado por pares]

New York, NY: Elsevier Inc

Texto completo disponível

Citações Citado por

Enviar para

Título:
Long-Term Failure Patterns and Survival in a Randomized Dose-Escalation Trial for Prostate Cancer. Who Dies of Disease?
Autor: Kuban, Deborah A., M.D ; Levy, Lawrence B ; Cheung, M. Rex, M.D. Ph.D ; Lee, Andrew K., M.D., M.P.H ; Choi, Seungtaek, M.D ; Frank, Steven, M.D ; Pollack, Alan, M.D., Ph.D
Assuntos: Age Factors ; Aged ; Biological and medical sciences ; BODY ; Cause of Death ; DEATH ; DISEASES ; Dose escalation ; DOSES ; Failure patterns ; FAILURES ; Follow-Up Studies ; GLANDS ; Gynecology. Andrology. Obstetrics ; Hematology, Oncology and Palliative Medicine ; Humans ; Male ; Male genital diseases ; MALE GENITALS ; MATHEMATICS ; Medical sciences ; MEDICINE ; Neoplasm Recurrence, Local - blood ; Neoplasm Recurrence, Local - mortality ; Neoplasm Staging ; NEOPLASMS ; Nephrology. Urinary tract diseases ; NUCLEAR MEDICINE ; ORGANS ; PROSTATE ; Prostate cancer ; Prostate-Specific Antigen - blood ; Prostatic Neoplasms - blood ; Prostatic Neoplasms - mortality ; Prostatic Neoplasms - pathology ; Prostatic Neoplasms - radiotherapy ; RADIATION DOSES ; RADIOLOGY ; RADIOLOGY AND NUCLEAR MEDICINE ; RADIOTHERAPY ; Radiotherapy Dosage ; REGRESSION ANALYSIS ; STATISTICS ; Survival ; THERAPY ; Time Factors ; Tumors ; Tumors of the urinary system ; Urinary tract. Prostate gland
É parte de: International journal of radiation oncology, biology, physics, 2011-04, Vol.79 (5), p.1310-1317
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-News-1
ObjectType-Feature-3
content type line 23
Descrição: Purpose To report long-term failure patterns and survival in a randomized radiotherapy dose escalation trial for prostate cancer. Materials and Methods A total of 301 patients with Stage T1b-T3 prostate cancer treated to 70 Gy versus 78 Gy now have a median follow-up of 9 years. Failure patterns and survival were compared between dose levels. The cumulative incidence of death from prostate cancer versus other causes was examined and regression analysis was used to establish predictive factors. Results Patients with pretreatment prostate-specific antigen (PSA) >10 ng/mL or high-risk disease had higher biochemical and clinical failures rates when treated to 70 Gy. These patients also had a significantly higher risk of dying of prostate cancer. Patients <70 years old at treatment died of prostate cancer nearly three times more frequently than of other causes when they were radiated to 70 Gy, whereas those treated to 78 Gy died of other causes more frequently. Patients age 70 or older treated to 70 Gy died of prostate cancer as often as other causes, and those receiving 78 Gy never died of prostate cancer within 10 years of follow-up. In regression analysis, factors predicting for death from prostate cancer were pretreatment PSA >10.5 ng/mL, Gleason score 9 and 10, recurrence within 2.6 years of radiation, and doubling time of <3.6 months at the time of recurrence. Conclusions Moderate dose escalation (78 Gy) decreases biochemical and clinical failure as well as prostate cancer death in patients with pretreatment PSA >10 ng/mL or high-risk disease.
Editor: New York, NY: Elsevier Inc
Idioma: Inglês

Links

Voltar para lista de resultados

Anterior Resultado 6 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Long-Term Failure Patterns and Survival in a Randomized Dose-Escalation Trial for Prostate Cancer. Who Dies of Disease?

Kuban, Deborah A., M.D ; Levy, Lawrence B ; Cheung, M. Rex, M.D. Ph.D ; Lee, Andrew K., M.D., M.P.H ; Choi, Seungtaek, M.D ; Frank, Steven, M.D ; Pollack, Alan, M.D., Ph.D

New York, NY: Elsevier Inc

Buscando em bases de dados remotas. Favor aguardar.